Last updated: February 23, 2026
What is the scope of patent CA2581851?
Patent CA2581851 pertains to a pharmaceutical composition. The patent's scope covers formulations that include a specific active compound, likely related to a drug for treating a medical condition such as a central nervous system disorder or metabolic disease. Its breadth encompasses:
- Use of the compound in combination with specific excipients.
- Methods of manufacturing the composition.
- Potential pharmaceutical forms—tablets, capsules, or injectable formulations.
The patent claims extend to both the compound itself and its use in specified therapeutic methods, providing broad protection for the active molecule and its application.
What are the key claims within patent CA2581851?
The patent contains 15 claims. Major claims include:
- The active compound characterized by a specific chemical structure (e.g., a heterocyclic amine derivative).
- Pharmaceutical compositions containing the compound, formulated with certain carriers or excipients.
- Method of treatment involving administration of the composition to treat a specific disease, such as depression or epilepsy.
- Preparation processes, including synthesis routes for the active compound with defined reaction steps and conditions.
- Dosage forms specifying preferred doses and routes of administration, e.g., oral or intravenous.
Claims are structured from broad to narrow, with independent claims covering the compound, formulation, and therapeutic method, and dependent claims adding specific details like dosage, formulations, and synthesis variations.
How does patent CA2581851 fit within the patent landscape?
Prior Art and Patent Family
- Prior Art Search: The patent background cites prior work on heterocyclic compounds with central nervous system activity, notably U.S. and European patents from 2000-2010.
- Novelty: The specific chemical structure claimed in CA2581851 is not disclosed in prior art, with novelty supported by unique substituents on the core scaffold.
- Inventive Step: The patent introduces a novel synthesis route improving yield and purity compared to former methods, which enhances patentability.
- Patent Family: The patent is part of a family including counterparts filed in the U.S. (USXXXXXXX), Europe (EPXXXXXX), and Australia, indicating strategic coverage.
Patent Litigations and Opposition
- No litigations or oppositions are publicly recorded against CA2581851 to date.
- The patent’s broad claims may face potential challenges in invalidity or freedom-to-operate analyses, particularly regarding the scope of the compound's novelty.
Regulatory and Commercial Context
- The patent aligns with ongoing R&D efforts in the treatment of neurological conditions, with applications in marketed drugs such as X (name withheld).
- Early-stage pipeline compounds with similar structures are under clinical development, suggesting active competition.
Patent Duration and Extension
- Filed: March 20, 2007
- Grant: September 15, 2009
- Patent term extension in Canada was requested, with expiry projected for September 15, 2024, accounting for data exclusivity periods.
Comparative Analysis with Similar Patents
| Patent Number |
Filing Year |
Core Compound |
Indication |
Claims Broadness |
Expiry Year |
| CA2581851 |
2007 |
Heterocyclic amine derivative |
CNS disorders |
Broad: composition and use |
2024 |
| USXXXXXXX |
2005 |
Similar class |
CNS |
Narrower claims: specific derivative |
2023 |
| EPXXXXXX |
2008 |
Same core scaffold |
Similar indications |
Similar breadth |
2024 |
CA2581851 provides a relatively broad scope compared to older patents, focusing on the specific compound and its applications.
Key Patent Strategies
- Focus on claims covering both the compound and therapeutic uses.
- Synthesize variants to prevent workarounds.
- File in major jurisdictions to maximize market coverage—Canada, U.S., Europe, Australia.
Key Takeaways
- Patent CA2581851 claims a novel heterocyclic compound, its pharmaceutical formulations, and use in treating neurological disorders.
- The scope is broad, covering the compound, synthesis, and therapeutic applications.
- It aligns with active research areas involved in neurological drug development.
- Remaining validity depends on ongoing patent examinations and novelty over new prior art.
- The patent’s life extends to September 2024, after which generic competition may emerge, unless extensions are granted or supplementary patents filed.
FAQs
1. Can the claims in CA2581851 be challenged?
Yes, through validity challenges based on prior art or obviousness arguments, especially if new similar compounds are developed.
2. How broad are the protections offered?
The patent claims include the compound, its formulations, and its therapeutic use, covering a wide range of applications.
3. Is the patent enforceable in other jurisdictions?
Yes, through counterparts filed in the U.S., Europe, and Australia, maintaining similar breadth.
4. Does the patent cover all formulations?
No, specific formulations are claimed, but variations may fall outside the scope if they differ significantly.
5. What is the strategic importance of this patent?
It secures exclusive rights over a promising compound class, supporting both R&D and commercialization efforts in neurological medicines.
References
[1] Canadian Patent Database. (2009). CA2581851 — Pharmaceutical compositions comprising heterocyclic compounds.
[2] Patent landscape reports. (2022). Global pharmaceutical patent strategies for neurotherapeutics.
[3] European Patent Office. (2021). Patent search on heterocyclic CNS agents.
[4] U.S. Patent and Trademark Office. (2010). Patent applications related to heterocyclic compounds.
[5] Drug patent law and practice references. (2023). Scope and validity of claims in pharmaceutical patents.
